ID: ALA5073517

Max Phase: Preclinical

Molecular Formula: C43H52FN7O9S

Molecular Weight: 861.99

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H](NC(=O)COCCOCCOCC(=O)Nc2ccc(C(=O)Nc3ccc(F)cc3N)cc2)C(C)(C)C)cc1

Standard InChI:  InChI=1S/C43H52FN7O9S/c1-26-38(61-25-47-26)28-7-5-27(6-8-28)21-46-41(56)35-20-32(52)22-51(35)42(57)39(43(2,3)4)50-37(54)24-60-18-16-58-15-17-59-23-36(53)48-31-12-9-29(10-13-31)40(55)49-34-14-11-30(44)19-33(34)45/h5-14,19,25,32,35,39,52H,15-18,20-24,45H2,1-4H3,(H,46,56)(H,48,53)(H,49,55)(H,50,54)/t32-,35+,39+/m1/s1

Standard InChI Key:  PZHPXXZQHPOAGY-PRDAUTAQSA-N

Associated Targets(Human)

VHL/Histone deacetylase 3 77 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 1 90 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VHL/Histone deacetylase 2 81 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 861.99Molecular Weight (Monoisotopic): 861.3531AlogP: 3.89#Rotatable Bonds: 19
Polar Surface Area: 223.54Molecular Species: NEUTRALHBA: 12HBD: 6
#RO5 Violations: 3HBA (Lipinski): 16HBD (Lipinski): 7#RO5 Violations (Lipinski): 3
CX Acidic pKa: 11.95CX Basic pKa: 2.78CX LogP: 1.72CX LogD: 1.72
Aromatic Rings: 4Heavy Atoms: 61QED Weighted: 0.06Np Likeness Score: -1.03

References

1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT..  (2022)  Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.,  65  (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179]

Source